Long-term fracture risk in patients with Crohn's disease: A population-based study in Olmsted County, Minnesota

2002 ◽  
Vol 123 (2) ◽  
pp. 468-475 ◽  
Author(s):  
Edward V. Loftus ◽  
Cynthia S. Crowson ◽  
William J. Sandborn ◽  
William J. Tremaine ◽  
William M. O'Fallon ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Fracture Risk ◽  
Population Based ◽  
Olmsted County ◽  
Population Based Study

scholarly journals Epidemiologic aspects of Crohn's disease: a population based study in Olmsted County, Minnesota, 1943-1982.

Gut ◽  
1988 ◽  
Vol 29 (1) ◽  
pp. 49-56 ◽  
Author(s):  
J H Gollop ◽  
S F Phillips ◽  
L J Melton ◽  
A R Zinsmeister
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Population Based ◽  
Olmsted County ◽  
Population Based Study

scholarly journals P137 Long-term outcome of paediatric-onset Crohn's disease: A population-based study

2012 ◽  
Vol 6 ◽  
pp. S64 ◽  
Author(s):  
A. Peneau ◽  
J. Salleron ◽  
M. Fumery ◽  
G. Savoye ◽  
E. Lerebours ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Population Based ◽  
Term Outcome ◽  
Population Based Study ◽  
Long Term Outcome

103 Long-Term Outcome of Paediatric-Onset Crohn's Disease: A Population-Based Study

2012 ◽  
Vol 142 (5) ◽  
pp. S-25 ◽  
Author(s):  
Anaïs Peneau ◽  
Julia Salleron ◽  
Mathurin Fumery ◽  
Guillaume Savoye ◽  
Eric Lerebours ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Population Based ◽  
Term Outcome ◽  
Population Based Study ◽  
Long Term Outcome

scholarly journals Long-term Fracture Risk in Patients with Celiac Disease: A Population-Based Study in Olmsted County, Minnesota

2007 ◽  
Vol 53 (4) ◽  
pp. 964-971 ◽  
Author(s):  
Mohammed R. Jafri ◽  
Charles W. Nordstrom ◽  
Joseph A. Murray ◽  
Carol T. Van Dyke ◽  
Ross A. Dierkhising ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Fracture Risk ◽  
Population Based ◽  
Olmsted County ◽  
Population Based Study

Sa1881 Long Term Outcomes and Predictors of Disabling Disease and Bowel Damage During Crohn's Disease: A Population-Based Study of Incident Cases Diagnosed Between 1994 and 1997

2016 ◽  
Vol 150 (4) ◽  
pp. S390
Author(s):  
Rabilloud Marie-Laure ◽  
Emma Bajeux ◽  
Siproudhis Laurent ◽  
Tron Isabelle ◽  
Michel Robaszkiewicz ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Population Based ◽  
Long Term Outcomes ◽  
Population Based Study ◽  
Incident Cases

scholarly journals P405 Comparison of long-term outcomes of infliximab vs. adalimumab in 1488 biologic-naive Korean patients with Crohn’s disease

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S374-S374
Author(s):  
Y S Jung ◽  
M Han ◽  
S Park ◽  
J H Cheon
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Population Based ◽  
Long Term Outcomes ◽  
Population Based Study ◽  
Korean Patients ◽  
Asian Patients ◽  
Significant Difference

Abstract Background Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patients with Crohn’s disease (CD) are rare, particularly for Asian patients. We compared the clinically key outcomes (surgery, hospitalisation, and corticosteroid use) of these two drugs in biologic-naive Korean patients with CD. Methods Using National Health Insurance claims, we collected data on patients who were diagnosed with CD and exposed to IFX or ADA between 2010 and 2016. Results We included 1488 new users of biologics (1000 IFX users and 488 ADA users). Over a median follow-up of 2.1 years after starting biological therapy, there were no significant differences in the risk of surgery (ADA vs. IFX; adjusted hazard ratio [aHR], 1.30; 95% confidence interval [CI], 0.86–1.95), hospitalisation (aHR, 1.05; 95% CI, 0.84–1.32), and corticosteroid use (aHR, 0.84; 95% CI, 0.58–1.22) between IFX and ADA users. These results were unchanged even when only patients who used biologics for over 6 months were analysed (aHR [95% CI]; surgery: 1.41 [0.88–2.26], hospitalisation: 1.06 [0.83–1.35], and corticosteroid use: 0.82 [0.56–1.21]). Additionally, these results were stable in patients treated with biological monotherapy or combination therapy with immunomodulators. Conclusion In this nationwide population-based study, there was no significant difference in the long-term effectiveness of IFX and ADA in the real-world setting of biologic-naive Korean patients with CD. In the absence of trials to directly compare IFX and ADA, our study supports that the choice of one of these two biologics may be allowed to be determined by the preference of patients and/or physicians.

Risk of fracture in Crohn's disease: A population-based study

2001 ◽  
Vol 120 (5) ◽  
pp. A628-A628
Author(s):  
E LOFTUSJR ◽  
C CROWSON ◽  
W SANDBORN ◽  
W TREAMINE ◽  
W OFALLON ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Population Based ◽  
Population Based Study ◽  
Risk Of Fracture
Sign in / Sign up

Export Citation Format

Share Document